ACT, we preselected gene pairs whose relative expression orderings were significantly correlated with the disease-free survival of patients by univariate Cox proportional hazards model. Then, from the identified prognostic-related gene pairs, a forward-stepwise selection algorithm was formulated to search for an optimal subset of gene pairs that resulted in the highest concordance index, referred to as the gene pair signature (GPS). We identified prognostic signatures, 3-GPS and 5-GPS, for predicting response to 5-FU-based ACT of patients with RCC and LCC, respectively, which were validated in independent datasets of GSE14333 and GSE72970. With the aid of the signatures, the transcriptional and genomic characteristics between the predicted responders and non-responders were explored. Notably, both in RCC and LCC, the predicted responders to 5-FU-based ACT were characterized by hypermutation, whereas the predicted non-responders were characterized by frequent copy number alternations. Finally, in comparison with the established relative expression ordering-based signature, which was developed without considering the differences between RCC and LCC, the newly proposed signatures had a better predictive performance. In conclusion, 3-GPS or 5-GPS can robustly predict response to 5-FUbased ACT for patients with RCC or LCC, respectively, in an individual level. 5 † Song, Zhao and Wang equally contributed to this work. 
5-Fluorouracil (5-FU) is an antimetabolite drug that is widely
used for the treatment of cancer through inhibition of thymidylate synthase and incorporation of its metabolites into RNA and DNA. 6 Currently, 5-FU-based adjuvant chemotherapy (ACT) is widely used as first-line systemic treatment for patients with high-risk stage II and stage III colon cancer. 7 Previous studies have revealed that only a certain group of patients respond to initial chemotherapy treatment 8 and the therapy response is influenced by the anatomic locations (left and right) of the primary tumors. 9 For conventional 5-FUbased ACT, when compared with patients treated with curative surgery only, a significant survival benefit was seen for patients with RCC who were treated with the therapy, but patients with LCC did not share the results, 9 which showed the difference in response to 5-FU-based ACT for RCC and LCC. Current signatures 10, 11 for predicting response to 5-FU-based ACT for stage II-III colon cancer patients did not take into account the anatomic locations of the primary tumors. Therefore, it would be promising to develop a new location-specific predictive signature to select patients most likely to benefit from the 5-FU-based ACT after surgery.
Another limitation of current transcriptional signatures is that they are based on the risk scores summarized from the gene expression levels of signature genes. 10, 11 These risk-score based signatures are often unfit for clinical applications due to the requirement of data normalization to remove the measurement batch effects, which needs a precollection of samples, whereas the risk score for a sample is influenced by the risk composition of the other samples. 12 In addition, the gene expression measurement values would also be greatly affected by sampling locations in tumor tissue 13 and partial RNA degradation during sample preparation, 14 introducing further uncertainty for the risk score and risk classification of a patient. In contrast, the relative expression orderings (REOs) of gene pairs within a sample have been found to be robust against experimental batch effects, 12 differences of measurement principles of different platforms, 15 uncertainties of sampling locations in a tumor tissue, 13 and partial RNA degradation, 16 which make it a promising approach for developing robust gene pair-based signatures (GPS). 17 In this work, based on the difference in response to 5-FU-based ACT for patients with different primary tumor locations of colon cancer, we developed REO-based signatures for predicting response to 5-FU-based ACT for stage II-III patients with RCC or LCC, which was validated in independent datasets. Transcriptional and genomic characteristics were analyzed between predicted responders and non-responders. Finally, we compared an established signature developed without considering the difference in anatomy location with the newly proposed signatures.
| MATERIALS AND METHODS

| Data and preprocessing
The gene expression datasets used in this study were downloaded from the Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/ge o/) and The Cancer Genome Atlas (http://cancergenome.nih.gov/) 3 (Table 1) . For samples documented in GSE39582, which were used as the discovery cohort to train REO-based predictive signatures of 5-FU-based ACT, the agents used for patients were fluorouracil and folinic acid. 18 For samples documented in GSE14333, the agents used for patients were either single agent 5-FU/capecitabine or 5-FU and oxaliplatin. 19 For samples documented in GSE72970, the agents used for patients were 5-FU, leucovorin, and oxaliplatin (FOLFOX). 20 Considering the small sample size of RCC and LCC in GSE14333 and GSE72970, the two cohorts were combined as the validation cohort to test the predictive signatures. The raw data (.CEL files) from each dataset was processed using the Robust Multi-array Average algorithm for background adjustment with quantile normalization. Probe identifiers (IDs) were mapped to gene IDs using the corresponding platform files.
If multiple probe-sets were mapped to the same gene, the expression value for the gene was summarized as the arithmetic mean of the values of multiple probe-sets. Probe-set IDs with no mapped Entrez gene ID or probe-set IDs that mapped to more than one Entrez gene ID were deleted. For data archived in TCGA, primary tumors originating in the splenic flexure, descending colon, or sigmoid colon were classified as LCC, whereas primary tumors originating in the appendix, cecum, ascending colon, hepatic flexure, or transverse colon were classified as RCC. Patients treated with neoadjuvant chemotherapy were excluded.
For transcriptional data derived from HTSeq sequencing platform (Illumina, San Diego, CA, USA), the raw count and FPKM values were extracted. For gene mutation data derived from the Illumina Genome
Analyzer DNA Sequencing GAIIx platform, only the non-synonymous mutations were included, and a discrete mutation profile including 15 922 genes was generated. Data of copy number aberrations (CNAs)
were processed with the GISTIC algorithm. 21 
| Survival analysis
Disease-free survival (DFS) was defined as the time from surgery to recurrence or the final documented date (censored). Survival curves were estimated using the Kaplan-Meier method and two survival curves were compared using the log-rank test 22 and 95% confidence intervals (CIs) were calculated using a univariate Cox proportional hazards model. 23 The multivariate Cox proportional hazards regression model was used to evaluate the independent prognostic value of the signature after adjusting for clinical factors. high-risk; otherwise, this sample was classified into the low-risk group. Patients predicted to be at high risk were thought to be unable to benefit from 5-FU-based ACT, that is, predicted nonresponders (termed non-responders for simplicity). Patients predicted to be at low risk were thought to benefit from 5-FU-based ACT, that is, predicted responders (termed responders for simplicity).
| Differential expression analysis and consistency evaluation
To estimate the significance of differences in gene expression among sample subgroups, different algorithms were used for microarray and RNA sequencing (RNASeq) data. For microarray data, Student's t-test was used to identify differentially expressed (DE) genes between two subgroups. For RNASeq data archived in TCGA, an EdgeR package 24 that uses a negative binomial model was used to detect DE genes from raw count data. The P-values were adjusted using the Benjamini-Hochberg procedure for multiple testing to control the false discovery rate (FDR).
If two lists of DE genes had k overlapped genes, among which s genes showed the same deregulation directions (up-or downregulation)
in the two DE gene lists, then the concordance score was calculated as s/k. The probability of observing a concordance score of s/k by chance was evaluated by the cumulative binomial distribution model as follows:
Where P 0 is the probability of one gene having the concordant relationship between the two lists of genes by chance (here,
The significance of a score indicated that DE genes extracted from an independent dataset were significantly consistent.
| Functional enrichment analyses
The functional categories for enrichment analysis were downloaded from the Kyoto Encyclopedia of Genes and Genomes (KEGG). 25 The hypergeometric distribution model was used to test whether a set of genes observed in a functional term was significantly more than that expected by random chance.
| Statistical analysis software
All statistical analyses were carried out using the R 3.1.3 software package (http://www.r-project.org/). whose expressions levels were significantly correlated with the DFS (univariate Cox regression model, P < .01). Then, from all the gene pairs formed by these prognosis-related genes, we further extracted 23 171 gene pairs whose specific REO patterns were significantly correlated with the DFS of patients (univariate Cox regression model, FDR < 0.05). Furthermore, using a forward selection procedure, we extracted three gene pairs that achieved the highest C-index according to the classification rule as follows: a sample was determined to be at high risk (non-responder) if at least one-half of the gene pairs'
| RESULTS
| Survival analyses
REOs within this sample voted for high-risk; otherwise, the sample was considered as low-risk (responder) (see Materials and Methods).
Thus, the three gene pairs (SEC23B-TPRG1L, EFCAB11-DPY19L1, and BCL2L12-LINC00294) consisting of six genes were selected as the predictive signature for predicting 5-FU-based therapeutic benefit for patients with RCC, denoted as 3-GPS. Using the same process, a predictive signature consisting of five gene pairs (NDRG3-KLK6, ARHGAP44-MAGEA6, C2CD4A-DNMBP, SPINK1-FXYD3, and PRR15L-ZNF706) for patients with LCC was developed, denoted as 5-GPS.
Using 3-GPS, 42 patients with RCC in the discovery cohort were predicted to be responders and their 5-year DFS rate was 85.6%, which was significantly higher than the corresponding rate (38.3%)
for the other 27 patients with RCC predicted to be non-responders Patients treated with chemotherapy harbor some adverse prognostic factors after surgery, 7 and should have worse prognosis than those treated with curative surgery alone, if they had not been treated with chemotherapy after surgery. Based on this fact, we estimated the survival benefit from 5-FU-based ACT for the predicted groups. For samples documented in the discovery cohort of GSE39582, the DFS of predicted responders was not significantly different from that of patients treated with curative surgery alone, both for RCC and LCC (RCC, log-rank P = .086;
LCC, log-rank P = .476) ( Figure 2E,F) . In contrast, the DFS of predicted non-responders was significantly shorter than that of patients treated with curative surgery alone, both for RCC and LCC (RCC, log-rank P = 2.08E-04; LCC, log-rank P = 5.73E-14)
( Figure 2I,J) . Similar results were observed in the validation dataset ( Figure 2G ,H,K,L). Thus, we can conclude that the predicted responders obtained absolute survival benefit from ACT, whereas the predicted non-responders had no significant survival benefit from ACT. Figure 3A ). We defined these 352 reproducible DE genes as 5-FU response-related genes for RCC, which were significantly enriched in 32 KEGG pathways (FDR < 10%, hypergeometric test; Figure 3B ), 13 of which have been reported to be associated with the efficacy of 5-FU. [26] [27] [28] [29] [30] [31] [32] [33] [34] For example, pyruvate metabolism is associated with chemosensitivity to 5-FU therapy. 33 Similarly, 446 DE genes were identified as 5-FU response-related genes for LCC, which were significantly enriched in 28 KEGG pathways (FDR < 10%, hypergeometric test; Figure 3C ,D), nine of which have been reported to be associated with 5-FU therapy. [35] [36] [37] [38] [39] [40] [41] [42] [43] For example, activation of the Akt pathway in colorectal cancer could induce resistance to 5-FU therapy. Table S1 ). Impressively, five chromosome regions (83.33%, one amplification and four deletions) had significantly higher CNA frequencies in the non-response group compared with the response group. Many genes in these chromosome lesions, such as ABCC10 (amp 6p21.1), 44 INSM1 (amp 20p11.23), 45 and MSH2 (del 2p21) 6 are known to be related to 5-FU resistance. For 86 samples with mutation data, we found 122 genes with significantly different mutation frequencies between the 30 non-responders and 56
F I G U R E 2 Performance of gene pair signatures 3-GPS and 5-GPS in identifying high-risk colon cancer patients. The Kaplan-Meier curves of disease-free survival (DFS) for the high-and low-risk groups of patients with right-sided colon cancer (RCC) and left-sided colon cancer (LCC) predicted by 3-GPS and 5-GPS in the discovery cohort (A) and validation cohort (C). (B,D) Multivariate Cox analysis. (E-L) Kaplan-Meier curves of DFS for responders (R) and non-responders (NR) in patients treated with non-adjuvant chemotherapy (ACT
Genomic characteristics between responders and non-responders to adjuvant chemotherapy for colon cancer, predicted by gene pair signatures (3-GPS). Genomic lesions between the two groups with the most significant difference for right-sided colon cancer (RCC) (Fisher's exact test, P < .05) are displayed. responders (Fisher's exact test, P < .05) ( Figure 4B , Table S1 ).
Impressively, 105 (86.07%) genes had significantly higher somatic mutation frequencies in the responders than in the non-responders.
Additionally, we found that the median of the mutation count per sample for the responders was 158, which was significantly more than the corresponding median count (105.5) for the non-responders (Student's t-test, P = .024). Many mutation genes are known to be related to 5-FU resistance. For example, PTEN, mutated in 21.43%
of the responders but none of the non-responders, the mutation of which could influence regulation of the PI3K/Akt signaling pathway, is correlated with 5-FU ACT sensitivity. 46 For another example, FBXW7, mutated in 23.21% of the responders but only 3.3% of nonresponders, is associated with RORa phosphorylation and thus influences 5-FU resistance. 47 As shown in Figure 4C ,D and Table S1 , the genomic characteristics of patients with LCC were also explored. Two chromosome regions (amp 5q22.3 and 19p13.2) and 60 genes with significantly different CNA and mutation frequencies were identified (Fisher's exact test, P < .05). MicroRNA-23a and microRNA-27a, located in 19p13.2, have been reported to influence 5-FU treatment. 48 Similarly, both of these chromosome regions had significantly higher CNA frequencies in the non-responders compared with the responders, which did not overlap with those identified in the RCC.
Additionally, 57 of the 60 genes had significantly higher somatic mutation frequencies in the responders than in the non-responders.
Taken together, these results clearly showed that the responders are characterized by several genomic lesions related to 5-FU resistance.
| Comparison of 5-FU response mechanisms between RCC and LCC
Transcriptional analysis showed that 5-FU response-related genes for RCC overlapped with 11 genes for LCC and the consistency score was 100%. The 11 genes were enriched in four KEGG pathways (ECM-receptor interaction, phagosome, focal adhesion, and the PI3K-Akt signaling pathway; FDR < 10%, hypergeometric test), three of which were well-known 5-FU response-related pathways. [36] [37] [38] In addition, there were two genes (CACNA1D and CNTN5) hypermutated in responders compared to non-responders both for patients with RCC and LCC. CACNA1D can enhance the benefit of 5-FUbased ACT through regulating activity of the calcium channel. 49 These transcriptional and genomic characteristics could shape 5-FU response and should be irrelevant of the primary tumor location of colon cancer patients.
However, it is worthwhile to note that both in the discovery and Colon Cancer, 7 patients with a deficiency in MMR protein expression (dMMR) showed decreased benefit with 5-FU ACT. As dMMR were frequently characterized in patients with RCC, the DFS between the two predicted groups was compared after excluding patients with stage II-III RCC annotated with dMMR. Using samples archived in GSE39582, which were annotated with MMR status, the DFS of the predicted two groups was still found to be significantly different (log-rank P = 2.19e-05; Figure S5 ).
Chen et al. and Qi et al. have reported that patients with RCC
derived more benefit from 5-FU-based ACT than patients with LCC. 16, 17 Similarly, in this study, the response rates for patients with RCC to 5-FU-based ACT was higher than that for patients with LCC.
Moreover, the DFS of responders for RCC was higher though insignificant than that of responders for LCC. Genomic analyses showed that, both in RCC and LCC, responders were characterized by hypermutation, whereas non-responders were characterized by frequent copy number alternations. Thus, the predicted responders suffer similar molecular differences with RCC, 3 while the predicted non-responders suffer similar molecular differences with LCC. 4 In addition, DE genes between responders and non-responders for patients with LCC were specifically enriched in pathways related to drug catabolism, which could contribute to multidrug resistance in tumors. These characterizations could be the cause of the distinction in response to therapy, which need to be further explored.
Patients derived from the dataset of GSE39582 were treated with 5-FU/LV, 18 whereas patients derived from the dataset of GSE14333 and GSE72970 were treated with 5-FU/capecitabine or 5-FU, leucovorin, and oxaliplatin (FOLFOX), 19 all of which were initial therapy options for CRC. However, the addition of a biologic agent, such as bevacizumab, cetuximab, or panitumumab, might have differing efficacy based on the primary site of colon cancer. As there are no data available for this research, further efforts are needed.
The REO-based signatures are robust against experimental batch effects, 12 the differences of measurement principles of different platforms, 15 sampling locations in a tumor tissue, 13 and partial RNA degradation. 16 The robustness and simplicity of this 
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